{"id":"W4399571391","doi":"10.1200/jco.2024.42.16_suppl.tps8668","title":"FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Exon; Oncology; Chemotherapy; Internal medicine; Mutation; Cancer research; Gene; Genetics; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001425064,0.001538813,0.001596503,0.0004689946,0.000353561,0.001329481,0.001237225,0.001699182,0.01248941],"category_scores_gemma":[0.0009674929,0.0005419925,0.001822556,0.0004028808,0.0006552188,0.001151375,0.000484053,0.003319265,0.002290052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001076978,"about_ca_system_score_gemma":0.001240485,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001287279,"about_ca_topic_score_gemma":0.004699737,"domain_scores_codex":[0.9996814,0.0001565598,0.00001210112,0.00004229293,0.00003367831,0.00007398379],"domain_scores_gemma":[0.9996314,0.00007627236,0.00008755701,0.00002408668,0.00001930696,0.0001613139],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8774044,0.01369778,0.001563455,0.001518599,0.001255375,0.0001727295,0.000151259,0.002766502,0.01277086,0.001006775,0.0134316,0.07426085],"study_design_scores_gemma":[0.8400532,0.1449986,0.004399868,0.00009626296,0.0004176117,0.0002951373,0.00004833454,0.001935971,0.001193311,0.0006071232,0.005917565,0.00003700997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9466753,0.01267624,0.001735286,0.00332532,0.001414995,0.006535196,0.01193524,0.0008181262,0.01488432],"genre_scores_gemma":[0.9460722,0.006606663,0.002857637,0.005057274,0.0007557076,0.007336555,0.0131315,0.0001450174,0.01803744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01248941,"threshold_uncertainty_score":0.04178125,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1094437706771043,"score_gpt":0.5412324112596139,"score_spread":0.4317886405825095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}